This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Global Neurostimulation Industry


Chip Makers Struggle to Meet Quality Demand II-8

Market Growth Attracts New Investors II-8

Neurostimulation on a Rise with Growing Indications II-8

Neurostimulation Market Marked by High Entry Barriers II-8

Increasing Acceptance of Neurostimulation due to Advanced

Clinical Benefits II-9

Powering Neurostimulation Devices-The Key to Success II-9

Market Development Initiatives to Fuel Market Growth II-9

Exploring Market Opportunities - The Technology Way II-10

Neurostimulation Devices - Growing Awareness and Acceptance

Among Physicians II-10

Synergy with Pharma & Biotech Companies Creates New Avenues II-10

Third-Party Reimbursement - A Vital Role to Play II-11

4. COMPETITIVE SCENARIO II-12Few Players Dominate Neurostimulation Market II-12Worldwide Neurostimulation Market: Leading Players byProduct Segment II-12Table 2: Leading Players in the Global NeurostimulationMarket (2011): Percentage Share Breakdown of Value Sales forMedtronic, St. Jude Medical, Boston Scientific, Cyberonicsand Others (includes corresponding Graph/Chart) II-13

Table 3: World Neurostimulation Market (2012): Percentage

Share Breakdown of Value Sales for Pain, Deafness, Epilepsy,

Movement Disorders, Depression, Stroke, Incontinence,

Gastroparesis and Obesity (includes corresponding

Graph/Chart) II-13

Product Offerings of Leading Players in the Neurostimulation

Market II-14

Select Spinal Cord Stimulation Product Offerings of St. Jude

and Medtronic II-14

Stimulation Parameters of Select SCS Products II-15

Companies Researching Neurostimulator Applications by

Indication II-15

5. EMERGING THERAPIES IN NEURO STIMULATION II-16ElectroCore to Demonstrate GammaCore at EHMTIC 2012 II-16University of Alabama Develops DBS Therapy for Parkinson'sDisease II-16California Based Medical Center Innovates Brain-controlledProsthetic Limb II-16Toronto Western Hospital Develops DBS Therapy for AlzheimersDisease II-17SPR Therapeutics Successfully Demonstrates PNS Therapy inStroke Victim II-17


Attacking the Source of Pain - The Logic behind Neuromodulation II-18

Growth Prospects for Neuromodulation Industry II-18

7. PRODUCT OVERVIEW II-20Introduction to Neurostimulator II-20A Historical Note II-20Neurostimulation Devices by Product Segment II-20Spinal Cord Stimulation (SCS) II-21SCS - What it Treats II-22Segmentation by Type of Power Source II-22Implantable Pulse Generator Systems (IPGs) II-22Radio Frequency (RF) Systems II-22Market Assessment for RF Systems II-23Sacral Nerve Stimulation (SNS) II-23Deep Brain Stimulation (DBS) II-24Vagus Nerve Stimulation (VNS) II-24Gastric Electric Stimulation (GES) II-25Stimulation Device - How it Works II-25Neurostimulation & its Benefits II-25Prospective Application Areas for Neurostimulators - SelectIndications II-26Neurostimulation Indications and Use of Related Devices/Techniques in the US II-27Approved Indications for Spinal Cord Stimulation by GeographicRegions II-27Neurostimulation Devices - Technology & Safety Issues II-27

2 of 11

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,131.86 +47.37 0.28%
S&P 500 2,014.89 +15.91 0.80%
NASDAQ 4,838.6430 +8.1730 0.17%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs